Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged 12 to \<15 months or 18 to \<24 months during sentinel-cohort enrollment, Or,12 to \<24 months during expanded-cohort enrollment.~* Subjects must have received all vaccinations in the relevant National Immunization Program (NIP) for their age group.~* Subject is determined to be in good health by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with any meningococcal serogroup B vaccine.~* Previous vaccination with HAV vaccine, or requirement to receive nonstudy HAV vaccine during Stage 1 of the study.~* Contraindication to vaccination with any HAV vaccine or known latex allergy.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.~* A known or suspected disorder of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B-cell function or those receiving systemic immunosuppressive therapy. Subjects with terminal complement deficiency may be included.~* History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.~* Significant neurologic disorder or history of seizure (excluding simple febrile seizure).~* Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination until the end of Stage 1.~* Current chronic use of systemic antibiotics.~* Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination and/or during study participation.~* Any neuroinflammatory or autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- rLP2086 vaccine (Type: EXPERIMENTAL): Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months
- Control (Type: ACTIVE_COMPARATOR): Arm stratified by age:~≥12 to \<18 months and ≥18 to \<24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).